Potential of new anticoagulants in patients with cancer (Q37740303)

22 August 2017

1 reference

title

Potential of new anticoagulants in patients with cancer (English)

1 reference

22 August 2017

1 reference

1 reference

1

Jeffrey I Weitz

1 reference

22 August 2017

publication date

1 April 2010

1 reference

22 August 2017

1 reference

22 August 2017

volume

125 Suppl 2

1 reference

22 August 2017

page(s)

S30-5

1 reference

Trends in the incidence of deep vein thrombosis and pulmonary embolism: a 25-year population-based study

22 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2810%2970009-8

7 January 2021

Risk factors for deep vein thrombosis and pulmonary embolism: a population-based case-control study

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2810%2970009-8

7 January 2021

Venous thromboembolism in the hematologic malignancies.

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2810%2970009-8

7 January 2021

The Long-Term Clinical Course of Acute Deep Venous Thrombosis

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2810%2970009-8

7 January 2021

The clinical course of pulmonary embolism

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2810%2970009-8

7 January 2021

Prognosis of Cancers Associated with Venous Thromboembolism

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2810%2970009-8

7 January 2021

Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2810%2970009-8

7 January 2021

Low-Molecular-Weight Heparins

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2810%2970009-8

7 January 2021

Prevention of venous thromboembolism in the cancer surgical patient

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2810%2970009-8

7 January 2021

American Society of Clinical Oncology guideline: recommendations for venous thromboembolism prophylaxis and treatment in patients with cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2810%2970009-8

7 January 2021

Comparison of fixed-dose weight-adjusted unfractionated heparin and low-molecular-weight heparin for acute treatment of venous thromboembolism

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2810%2970009-8

7 January 2021

Low-molecular-weight heparins in renal impairment and obesity: available evidence and clinical practice recommendations across medical and surgical settings

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2810%2970009-8

7 January 2021

Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis.

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2810%2970009-8

7 January 2021

Incidence of recurrent thromboembolic and bleeding complications among patients with venous thromboembolism in relation to both malignancy and achieved international normalized ratio: a retrospective analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2810%2970009-8

7 January 2021

New anticoagulants for treatment of venous thromboembolism

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2810%2970009-8

7 January 2021

Clinical pharmacokinetics and pharmacodynamics of the oral direct thrombin inhibitor dabigatran etexilate

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2810%2970009-8

7 January 2021

https://api.crossref.org/works/10.1016%2FS0049-3848%2810%2970009-8

1 reference

7 January 2021

Safety, pharmacodynamics, and pharmacokinetics of BAY 59-7939--an oral, direct Factor Xa inhibitor--after multiple dosing in healthy male subjects

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2810%2970009-8

7 January 2021

Comparative pharmacodynamics and pharmacokinetics of oral direct thrombin and factor xa inhibitors in development

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2810%2970009-8

7 January 2021

Apixaban metabolism and pharmacokinetics after oral administration to humans

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2810%2970009-8

7 January 2021

Idraparinux versus standard therapy for venous thromboembolic disease

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2810%2970009-8

7 January 2021

Comparison of idraparinux with vitamin K antagonists for prevention of thromboembolism in patients with atrial fibrillation: a randomised, open-label, non-inferiority trial

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2810%2970009-8

7 January 2021

Dabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement: a randomised, double-blind, non-inferiority trial.

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2810%2970009-8

7 January 2021

Oral dabigatran etexilate vs. subcutaneous enoxaparin for the prevention of venous thromboembolism after total knee replacement: the RE-MODEL randomized trial.

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2810%2970009-8

7 January 2021

Oral thrombin inhibitor dabigatran etexilate vs North American enoxaparin regimen for prevention of venous thromboembolism after knee arthroplasty surgery

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2810%2970009-8

7 January 2021

Dabigatran versus warfarin in the treatment of acute venous thromboembolism

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2810%2970009-8

7 January 2021

Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2810%2970009-8

7 January 2021

Extended duration rivaroxaban versus short-term enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty: a double-blind, randomised controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2810%2970009-8

7 January 2021

Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2810%2970009-8

7 January 2021

Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty (RECORD4): a randomised trial

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2810%2970009-8

7 January 2021

Apixaban or enoxaparin for thromboprophylaxis after knee replacement

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2810%2970009-8

7 January 2021

Apixaban versus enoxaparin for thromboprophylaxis after knee replacement (ADVANCE-2): a randomised double-blind trial

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2810%2970009-8

7 January 2021

Double-blind randomised trial of a very-low-dose warfarin for prevention of thromboembolism in stage IV breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2810%2970009-8

7 January 2021

Nadroparin for the prevention of thromboembolic events in ambulatory patients with metastatic or locally advanced solid cancer receiving chemotherapy: a randomised, placebo-controlled, double-blind study

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2810%2970009-8

7 January 2021

10.1016/S0049-3848(10)70009-8

Identifiers

DOI

1 reference

22 August 2017

1 reference